In this Review, the authors examine the most recent clinical evidence for the use of sulfasalazine and mesalazine for the treatment of ulcerative colitis and Crohn's disease. Evidence for the role of mesalazine as a chemoprophylactic agent that protects against the development of colorectal cancer is also discussed.
- Ole H Nielsen
- Lars K Munck
